A & G Pharmaceutical, Inc.
Records under this name other than the patents A & G Pharmaceutical, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.
Back to A & G Pharmaceutical, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,674,460 | Compositions and methods for restoring sensitivity to treatment with HER2 antagonists Term ended Term ended Apr 12, 2026 · From the USPTO record | Term ended | Term ended Apr 12, 2026 | From the USPTO record |
| US 7,815,906 | Compositions and methods for restoring sensitivity to treatment with HER2 antagonists Term ended Term ended Oct 26, 2024 · From the USPTO record | Term ended | Term ended Oct 26, 2024 | From the USPTO record |
| US 7,651,854 | Methods for increasing the proliferation of B cells Term ended Term ended Oct 17, 2024 · From the USPTO record | Term ended | Term ended Oct 17, 2024 | From the USPTO record |
| US 7,560,095 | Cancer specific monoclonal antibodies Term ended Term ended Aug 7, 2024 · From the USPTO record | Term ended | Term ended Aug 7, 2024 | From the USPTO record |
| US 7,411,045 | Autocrine growth factor receptor antibodies and methods Term ended Term ended Jun 14, 2024 · From the USPTO record | Term ended | Term ended Jun 14, 2024 | From the USPTO record |
| US 7,368,428 | Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis Lapsed on the fee record Ended May 6, 2020 · From the USPTO record | Lapsed on the fee record | Ended May 6, 2020 | From the USPTO record |
| US 7,183,384 | Monoclonal antibody 7H11 reactive with human cancer Lapsed on the fee record Ended Feb 27, 2019 · From the USPTO record | Lapsed on the fee record | Ended Feb 27, 2019 | From the USPTO record |
| US 7,091,047 | Methods and kits for diagnosing tumorigenicity Term ended Term ended Aug 2, 2018 · From the USPTO record | Term ended | Term ended Aug 2, 2018 | From the USPTO record |
| US 7,592,318 | 88kDa tumorigenic growth factor and antagonists Term ended Term ended Jul 6, 2018 · From the USPTO record | Term ended | Term ended Jul 6, 2018 | From the USPTO record |
| US 6,824,775 | 88kDa tumorigenic growth factor and antagonists Term ended Term ended Jun 24, 2018 · From the USPTO record | Term ended | Term ended Jun 24, 2018 | From the USPTO record |